A photo of Charles Quinn.

Medical Director, Pediatric Sickle Cell Program

Director, Erythrocyte Diagnostic Laboratory

Professor, UC Department of Pediatrics

513-517-2234

513-636-5845

Board Certified

Best Doctors logo

My Biography & Research

Biography

Dr. Quinn conducts patient-oriented and translational research in sickle cell disease and thalassemia. He is the medical director of the Pediatric Sickle Cell Disease Program and the medical director of the Erythrocyte Diagnostic Laboratory at Cincinnati Children’s Hospital. He is also the medical director of the Ohio Department of Health Regional Sickle Cell Services Program – Region 1.

Clinical Interests

Sickle cell disease; thalassemia; hemoglobinopathies; genetics of hemoglobinopathies; anemia; autoimmune hemolytic anemia; disorders of red blood cells; iron overload and iron chelation; chronic transfusion therapy; hereditary spherocytosis (HS); hereditary xerocytosis (HX); immune thrombocytopenia (ITP).

Research Interests

Identifying the causes of the cardiomyopathy and nephropathy of sickle cell disease and identifying new treatments for these complications; direct measurement of red blood cell turnover (rate of hemolysis); MRI methods for the quantitation of tissue iron; new agents for immune thrombocytopenia (ITP).

Academic Affiliation

Professor, UC Department of Pediatrics

Clinical Divisions

Cancer and Blood Diseases, Sickle Cell and Hemoglobin Disorders, Cerebrovascular

Research Divisions

Hematology, Cancer and Blood Diseases

My Education

MD: University of Texas Southwestern Medical Center, Dallas, TX, 1994.

MS: University of Texas Southwestern Medical Center, Dallas, TX, 2008.

Residency & Chief Residency: Children's Medical Center Dallas, Dallas, TX; University of Texas Southwestern Medical Center, Dallas, TX, 1998.

Fellowship: Children's Medical Center Dallas, Dallas, TX; University of Texas Southwestern Medical Center, Dallas, TX, 2001.

Certifications: Pediatrics, 1998; Pediatric Hematology-Oncology, 2002.

My Publications

Left atrial dysfunction in sickle cell anemia is associated with diffuse myocardial fibrosis, increased right ventricular pressure and reduced exercise capacity. Alsaied, T; Niss, O; Tretter, JT; Powell, AW; Chin, C; Fleck, RJ; Cnota, JF; Malik, P; Quinn, CT; Nagueh, SM; et al. Scientific Reports. 2020; 10.

Severe infusion-related reaction to crizanlizumab in an adolescent with sickle cell disease. Karkoska, K; Quinn, CT; Clapp, K; McGann, PT. American Journal of Hematology. 2020; 95:E338-E339.

Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia. Meier, ER; Creary, SE; Heeney, MM; Dong, M; Appiah-Kubi, AO; Nelson, SC; Niss, O; Piccone, C; Quarmyne, MO; Quinn, CT; et al. Trials. 2020; 21.

Improving self-management in adolescents with sickle cell disease. Crosby, LE; Hood, A; Kidwell, K; Nwankwo, C; Peugh, J; Strong, H; Quinn, C; Britto, MT. Pediatric Blood and Cancer. 2020; 67.

Non-transfusion-dependent ß-thalassemia because of a single ß-thalassemia mutation and coinherited a-globin gene triplication: Need for increased awareness to prevent incorrect and delayed diagnosis. Gurunathan, A; Tarango, C; McGann, PT; Niss, O; Quinn, CT. Journal of Pediatric Hematology/Oncology. 2020; 42:e494-e496.

Non–transfusion-dependent β-Thalassemia Because of a Single β-Thalassemia Mutation and Coinherited α-Globin Gene Triplication: Need for Increased Awareness to Prevent Incorrect and Delayed Diagnosis. Gurunathan, A; Tarango, C; McGann, PT; Niss, O; Quinn, CT. Journal of Pediatric Hematology/Oncology. 2020; 42:e494-e496.

Disease Self-Efficacy and Health-Related Quality of Life in Adolescents with Sickle Cell Disease. Goldstein-Leever, A; Peugh, JL; Quinn, CT; Crosby, LE. Journal of Pediatric Hematology/Oncology. 2020; 42:141-144.

Clinical utility of confirmatory genetic testing to differentiate sickle cell trait from sickle-β+thalassemia by newborn screening. Shook, LM; Haygood, D; Quinn, CT. International Journal of Neonatal Screening. 2020; 6:7-7.

Vitamin D supplementation and pain-related emergency department visits in children with sickle cell disease. Hood, AM; Quinn, CT; King, CD; Shook, LM; Peugh, JL; Crosby, LE. Complementary Therapies in Medicine. 2020; 49:102342-102342.

L-glutamine for sickle cell disease: Knight or pawn?. Sadaf, A; Quinn, CT. Experimental biology and medicine (Maywood, N.J.). 2020; 245:146-154.